The overall goal is to determine the changes that occur in amyloid-beta (Aβ) metabolism in Alzheimer's disease (AD) and model the production, transport, metabolism and clearance of Aβ in the human central nervous system (CNS) and periphery to improve clinical trial designs and also possibly develop an AD blood test.